Skip to main content
. 2025 Apr 9;17(8):1270. doi: 10.3390/cancers17081270
PC Prostate cancer
3βHSD1 3β-Hydroxysteroid dehydrogenase type 1
DHEA Dehydroepiandrosterone
DHT Dihydrotestosterone
mCRPC Metastatic castration-resistant prostate cancer
AR Androgen receptor
ADT Androgen depravation therapy
OS Overall survival
ICI Immune checkpoint inhibitor
ER Estrogen receptor